Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test after delivery could prevent deadly preeclampsia

NCT ID NCT07185204

Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study in Nepal tests whether a blood test before delivery can predict which women will develop dangerous high blood pressure after giving birth. Women at high risk will receive a care bundle including remote blood pressure monitoring, education, and medication to manage their condition early. The goal is to see if this approach is feasible and reduces the need for emergency care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nifedipine ER (blood pressure medication)
What this could lead to
If successful, this could lead to a simple, scalable way to catch and treat postpartum preeclampsia early, reducing serious complications.
What could go wrong
This is a very small pilot study (60 people) focused on feasibility, not proof of effectiveness. The results may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant patients ≥ 36 weeks gestation without major fetal anomalies * Age ≥ 18 years * Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital * At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF * 1 or more high risk factors: * History of preeclampsia * Type 1 or 2 diabetes * Multifetal gestation? * Renal disease * Autoimmune disease * 2 or more moderate risk factors: * Nulliparity * BMI \> 30 * First-degree relative with a history of preeclampsia * African American race * Low socioeconomic status * Age \> 35 years * History of low birthweight or small for gestational age * Previous adverse pregnancy outcome * Interpregnancy interval \> 10 years Exclusion Criteria: * Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines * Chronic hypertension, according to ACOG guidelines * Known allergy or contraindication to nifedipine * Inability or unwillingness to provide informed consent * Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postpartum preeclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postpartum preeclampsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dhulikhel Hospital

    RECRUITING

    Dhulikhel, Nepal

  • Medical College of Wisconsin

    ACTIVE_NOT_RECRUITING

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.